Syro Luis V, Rotondo Fabio, Camargo Mauricio, Ortiz Leon D, Serna Carlos A, Kovacs Kalman
Department of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellin, Colombia.
Department of Laboratory Medicine, Division of Pathology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Front Endocrinol (Lausanne). 2018 Jun 15;9:318. doi: 10.3389/fendo.2018.00318. eCollection 2018.
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.
替莫唑胺是一种烷化剂，最初用于治疗胶质瘤，2006年其应用范围扩大至垂体瘤。经过12年的使用，替莫唑胺在垂体瘤治疗方面取得了显著进展，侵袭性垂体腺瘤和垂体癌的5年总生存率和5年无进展生存率均有显著提高。在本文中，我们综述了替莫唑胺作为烷化剂的作用机制、其与脱氧核糖核酸修复系统的相互作用、在垂体瘤中的治疗效果、未解决的问题以及与靶向治疗新可能性相关的未来方向。
